Iranian Company Produces Combined Oral Drug for Diabetes
Type 2 diabetes is a common condition that causes the level of sugar (glucose) in the blood to become too high. It is mainly the result of two problems: cells in muscle, fat and the liver become resistant to insulin. As a result, the cells don't take in enough sugar. The pancreas can't make enough insulin to keep blood sugar levels within a healthy range.
"TRYTIS which is tablet combined of metformin, empagliflozin and linagliptin with three different mechanisms of action, reduces blood sugar in diabetic patients. In the production of this drug, a combination of slow release technology and rapid release of active ingredients of the drug has been used for optimal and long-term control of blood sugar in diabetic patients,” Reza Karimi Mostofi, the managing director of a knowledge-based ActoverCo pharmaceutical company based in Alborze Province next to the capital Tehran, said.
“At least 11% of the country's population over 20 years of age suffer from diabetes, and nearly half of the sufferers are not aware of their disease. Today, the use of combination drugs with the lowest number of tablets taken per day and with high effectiveness has created a great evolution in the control of diabetes and increased the success of the treatment,” Karimi Mostofi said.
“Empagliflozin in TRYTIS tablets will reduce mortality rate resulting from the complications of cardiovascular diseases, heart failure or diabetic kidney diseases. Taking this drug in diabetics can reduce the risk of problems related to cardiovascular and kidney failure,” he explained.
The managing director of the knowledge-based company pointed to the campaign launched by the experts against diabetes, and said, “This pharmaceutical company has already produced drugs such as Glucophage, Empower, Empower +, Dipta, Dipta +, Sigomet, Glypover, Glodap, Gloda +, Glucovance, Glysta, and Glycover which have helped peope to treat diabetes in the country.”
“TRYTIS tablet, which was produced with the latest technology in ActoverCo pharmaceutical company, became available to diabetic patients in May of this year,” noted the managing director of the company.
“Nearly 400 pharmaceutical products in 15 therapeutic areas are being produced in this company, which includes a wide range of drugs for general diseases to oncology and high-risk, hormonal and biological drugs,” added Karimi Mostofi.
"The pharmaceutical group, which is also operating in the production of pharmaceutical raw materials and supplements, has many more medicine on agenda in the field of chemical and biological pharmaceutical production to control and treat non-transmittable diseases," he went on to say.
4155/i
